user

Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.

被引：0
|
作者：
Maiese, Eric
Graham, Christopher N.
Hawe, Emma
Le Moine, Jean-Gabriel
机构：
[1] Janssen Sci Affairs, LLC, Horsham, PA USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20037
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [2] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
  • [3] Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
    Spencer, Andrew
    Lentzsch, Suzanne
    Weisel, Katja
    Avet-Loiseau, Herve
    Mark, Tomer M.
    Spicka, Ivan
    Masszi, Tamas
    Lauri, Birgitta
    Levin, Mark-David
    Bosi, Alberto
    Hungria, Vania
    Cavo, Michele
    Lee, Je-Jung
    Nooka, Ajay K.
    Quach, Hang
    Lee, Cindy
    Barreto, Wolney
    Corradini, Paolo
    Min, Chang-Ki
    Scott, Emma C.
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Beksac, Meral
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Sonneveld, Pieter
    Soong, David
    Casneuf, Tineke
    Chiu, Christopher
    Amin, Himal
    Qi, Ming
    Thiyagarajah, Piruntha
    Sasser, A. Kate
    Schecter, Jordan M.
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2018, 103 (12) : 2079 - 2087
  • [4] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
  • [5] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [6] TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA
    van Beurden-Tan, C.
    Forero, J.
    Coggia, A.
    Bustos Marquez, M. C.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [7] Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma
    Chari, Ajai
    Dimopoulos, Meletios-Athanasios
    Beksac, Meral
    Leleu, Xavier
    Weisel, Katja
    Richter, Joshua
    Dirnberger, Franziska
    Iskander, Karim
    Yusuf, Akeem
    Mikhael, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S142 - S142
  • [8] Economic Evaluation of Carfilzomib plus Dexamethasone (Kd) Vs Bortezomib plus Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)
    Jakubowiak, Andrzej
    Majer, Istvan Matyas
    Houisse, Ivan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    BLOOD, 2016, 128 (22)
  • [9] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial
    Pelham, Robert J.
    Hu, Xuguang
    Moreau, Philippe
    Oriol, Albert
    Quach, Hang
    Kovacsovics, Tibor
    Keats, Jonathan J.
    Feng, Shibao
    Kimball, Amy S.
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
12345